Magrolimab, a first-in-class anti-CD47 antibody, has initially shown promising activity results when combined with azacitidine in AML patients, however, phase 3 trials were recently interrupted for futility, non-efficacy, and increased mortality. Here, CD47 is linked to acute myeloid leukemia.